SRPT
NASDAQ · Biotechnology
Sarepta Therapeutics Inc
$17.62
-0.09 (-0.51%)
Open$17.50
Previous Close$17.71
Day High$17.85
Day Low$17.25
52W High$103.32
52W Low$10.42
Volume—
Avg Volume2.58M
Market Cap1.82B
P/E Ratio—
EPS$-8.48
SectorBiotechnology
Analyst Ratings
Hold
33 analysts
Price Target
+125.9% upside
Current
$17.62
$17.62
Target
$39.80
$39.80
$34.71
$39.80 avg
$61.57
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.24B | 1.68B | 549.72M |
| Net Income | -726,904,203 | -491,631,308 | -107,586,925 |
| Profit Margin | -32.5% | -30.8% | -19.6% |
| EBITDA | -670,153,546 | -478,429,299 | -125,300,242 |
| Free Cash Flow | — | — | -79,607,758 |
| Rev Growth | +33.1% | +33.1% | +15.5% |
| Debt/Equity | 0.73 | 0.73 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |